142 related articles for article (PubMed ID: 24591764)
1. Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas.
Ponti G; Pellacani G; Tomasi A; Loschi P; Luppi G; Gelsomino F; Longo C
Dis Markers; 2014; 2014():671283. PubMed ID: 24591764
[TBL] [Abstract][Full Text] [Related]
2. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
3. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.
Henary H; Hong DS; Falchook GS; Tsimberidou A; George GC; Wen S; Wheler J; Fu S; Naing A; Piha-Paul S; Janku F; Kim KB; Hwu P; Kurzrock R
Ann Oncol; 2013 Aug; 24(8):2158-65. PubMed ID: 23576709
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.
Tseng D; Kim J; Warrick A; Nelson D; Pukay M; Beadling C; Heinrich M; Selim MA; Corless CL; Nelson K
J Am Acad Dermatol; 2014 Aug; 71(2):229-36. PubMed ID: 24842760
[TBL] [Abstract][Full Text] [Related]
5. Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.
Lee SH; Kim JE; Jang HS; Park KH; Oh BH; Shin SJ; Chung KY; Roh MR; Rha SY
Cancer Res Treat; 2018 Oct; 50(4):1378-1387. PubMed ID: 29361821
[TBL] [Abstract][Full Text] [Related]
6. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
Varada S; Mahalingam M
Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
[TBL] [Abstract][Full Text] [Related]
7. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
Lovly CM; Dahlman KB; Fohn LE; Su Z; Dias-Santagata D; Hicks DJ; Hucks D; Berry E; Terry C; Duke M; Su Y; Sobolik-Delmaire T; Richmond A; Kelley MC; Vnencak-Jones CL; Iafrate AJ; Sosman J; Pao W
PLoS One; 2012; 7(4):e35309. PubMed ID: 22536370
[TBL] [Abstract][Full Text] [Related]
8. [Translational research and diagnostics of melanoma].
Rüschoff J; Kleinschmidt M; Middel P
Pathologe; 2012 Nov; 33 Suppl 2():291-5. PubMed ID: 22968732
[TBL] [Abstract][Full Text] [Related]
9. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
10.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
11. Testing for
Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A
J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288
[TBL] [Abstract][Full Text] [Related]
12. Frequencies of KIT and GNAQ mutations in acral melanoma.
Puntervoll HE; Molven A; Akslen LA
J Cutan Pathol; 2014 Nov; 41(11):893-4. PubMed ID: 25363280
[No Abstract] [Full Text] [Related]
13. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study.
Taskin OC; Sari SO; Yilmaz I; Hurdogan O; Keskin M; Buyukbabani N; Gulluoglu M
Turk Patoloji Derg; 2023; 39(1):23-30. PubMed ID: 35642348
[TBL] [Abstract][Full Text] [Related]
14. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
15. Melanoma.
Schadendorf D; Fisher DE; Garbe C; Gershenwald JE; Grob JJ; Halpern A; Herlyn M; Marchetti MA; McArthur G; Ribas A; Roesch A; Hauschild A
Nat Rev Dis Primers; 2015 Apr; 1():15003. PubMed ID: 27188223
[TBL] [Abstract][Full Text] [Related]
16. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
17. Treatment implications of the emerging molecular classification system for melanoma.
Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
[TBL] [Abstract][Full Text] [Related]
18. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.
Turajlic S; Furney SJ; Stamp G; Rana S; Ricken G; Oduko Y; Saturno G; Springer C; Hayes A; Gore M; Larkin J; Marais R
Ann Oncol; 2014 May; 25(5):959-67. PubMed ID: 24504448
[TBL] [Abstract][Full Text] [Related]
19. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
[TBL] [Abstract][Full Text] [Related]
20. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
